InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,548.47
(
-0.71%
)
US TECH 100
19,140.00
(
-0.68%
)
Dow Jones
40,772.75
(
-1.03%
)
Brent Oil
84.59
(
0.12%
)
Bitcoin
63,429.99
(
-1.02%
)
Post# of 252638
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120077
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: OakesCS post# 202031

Tuesday, 07/26/2016 1:46:53 PM

Tuesday, July 26, 2016 1:46:53 PM

Post# of 252638
EXAS +30% on 2Q16 results—including 54K Cologuard tests—although the number-of-tests guidance for full-year 2016 remains unchanged at 240K:

http://finance.yahoo.com/news/exact-sciences-completes-54-000-090000824.html

Reimbursement by private payers is gradually improving. The unchanged 240K-test guidance for full-year 2016 may be deliberate lowballing.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up